COMPANY

Turn Therapeutics

Keywords: medical device medical devices Eczema Atopic Dermatitis Eczema Atopic Dermatitis Covid19 GX-03

Location: Westlake Village, CA · source · Oct 7, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $1.65M (Form D filed Aug 26, 2026). SEC Form D 0002023016-26-000001 (Aug 26, 2026)
Evidence (1 event)
- Aug 26, 2026 · SEC Form D 0002023016-26-000001
  Name of Issuer: Turn Therapeutics Inc.; CIK: 2023016; Address: Westlake Village, CA; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1650000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 11, 2025 Trial start 2: A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) source ↗
Dec 12, 2024 Raise Private placement: $75M (total, as published), announced Dec 12, 2024. Source: company's own press page. source ↗
Jan 21, 2021 Trial start Phase 2: Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. source ↗

Jan 20, 2027 (ESTIMATED) · 2 · A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) · NCT07355075

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $75.0M. Last 2 years.

Dec 12, 2024 Private placement: $75M (total, as published), announced Dec 12, 2024. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07355075	A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)	2	Recruiting	Jul 11, 2025	Jan 20, 2027 (estimated)
NCT04951349	Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.	Phase 2	Completed	Jan 21, 2021	May 30, 2021 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2026-08-26 Raise Private raise (SEC Form D): $1.6M sold; issuer “Turn Therapeutics Inc.”. Verified from the SEC filing. SEC filing ↗